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ABSTRACT 
Tumor necrosis factor-_ converting enzyme (TACE) mediates shedding of human 
epidermalgrowth factor receptor-4 (HER4). Recent data suggests that released HER4 
intracellulardomain (4ICD) induces apoptosis in breast cancer.TACE expression, as 
measured by immunohistochemistry, was observed in 183/383 breast carcinomas, 
39/217 ovarian carcinomas, and 16/24 and 17/24 hormone-sensitive and hormone 
insensitive prostate carcinomas, respectively. HER4 expression was detected in breast 
carcinomas, using two antibodies recognizing an extracellular or intracellular 
epitope.TACE expression was predominantly seen in tumors with high levels of 4ICD 
and membrane HER4. Apoptotic activity was measured by TUNEL assay and cleaved 
caspase-3staining in breast carcinomas. There was no significant association between 
cleaved caspase-3 or TUNEL positivity and 4ICD, whereas TUNEL positivity was 
seen predominantly in tumors with high levels of internalized HER4. The data 
presented here show TACE expression in endocrine cancers and further supports a 
role for TACE in breast cancer 
apoptosis. 
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INTRODUCTION 
Tumor necrosis factor-_ Converting Enzyme (TACE) is a zinc-dependent 
metalloproteinsedisintegrin 
membrane-anchored glycoprotein, which belongs to the ADAM protein family 
(reviewed in 1). This family of proteases is involved in the processing of many 
cleavable 
integral membrane proteins, but the physiological substrate for only a few of them has 
been 
identified. TACE or ADAM 17 is implicated in inflammatory conditions such as 
rheumatoid 
arthritis and inflammatory bowel disease 2-4, and was originally identified by its 
ability to 
cleave and activate TNF_ precursors 5,6. TACE also plays a central role in protein 
ectodomain shedding of a variety of structurally and functionally unrelated 
transmembrane 
molecules 7, and was recently identified as the proteinase responsible for cleavage of 
membrane-bound HER4 8. This indicates a central role for TACE also in non-
inflammatory 
conditions such as cancers. A role for TACE in cancer progression was further 
supported by 
the finding that TACE can regulate EGFR ligand availability as TACE-mediated 
activation 
of proTGF-_ was essential for activation of HER1 (EGFR) and thus its downstream 
signal 
transduction pathways such as PI3K/Akt or RAS/RAF/MAPK 9,10. 
The Human Epidermal growth factor Receptor (HER) family of type-1 receptor 
tyrosine 
kinases consists of four members, EGFR/HER1, HER2/ErbB-2, HER3/ErbB-3 and 
HER4/ErbB-4 11, which regulate cellular proliferation, differentiation and apoptosis in 
a 
growth-factor dependent manner 12-14. Aberrant HER signaling is a frequent 
phenomenon in 
various human cancers 15. Whilst the roles of EGFR and HER2 in cancer progression 
are 
well-characterized, and expression of these oncogenes is linked to poor patient 
outcome, the 
role of HER4 in tumor biology as well as its clinical relevance is still emerging 16. 
Conflicting reports have associated HER4 with adverse prognosis 17, however, HER4 
expression has also been associated with improved patient outcome 18, reduced tumor 
cell 
proliferation 19-21 and good clinicopathological markers such as lower tumor grade in 
primary, untreated, breast tumors 22. Upon ligand-induced activation, the HER 
receptors 
form receptor homo- and heterodimers and activate, through tyrosine kinase-mediated 
phosphorylation, downstream intracellular pathways, including the PI3K/Akt and 
Ras/Raf/MAPK signaling pathway, culminating in cellular responses including 
proliferation, 
differentiation and apoptosis 15 
Recent data suggests that the proteolytically processed intracellular domain of HER4 
plays an important role in mediating apoptosis of breast cancer cell lines 23,24. HER4 
cleavage within the extracellular domain is initially processed by the proteolytic 
activity of 
TACE 25 and subsequently by the activity of presenilin-dependent _-secretase 26, 
which 
releases the 80-kDa HER4 intracellular domain (4ICD) into the cytoplasm 27. This 
intracellular HER4 domain (4ICD) includes the tyrosine kinase domain and is able to 
translocate to the nucleus 26. During normal breast development and lactation, 4ICD 
functions as a nuclear chaperone for STAT5A regulating STAT5A transcriptional 
activation 
of the _-casein promoter 14,24. HER4 over expression has been observed in breast 
cancers 
21,28, and we have recently, using in vitro studies, identified 4ICD as a pro-apoptotic 
BH3- 
domain-only protein in breast cancer cell lines, integrating apoptotic signals at the 
mitochondria and initiating mitochondrial dysfunction 23. This role of HER4 in 
mediating 
improved patient outcome by affecting the level of apoptosis is not related to 
activation of 
the PI3K/Akt and Ras/Raf/MAPK signaling transduction pathways but requires 
presenilindependent 
_-secretase proteolytic processing. Indeed a HER4 variant (HER4-V673I) which 
lacks a _-secretase cleavage site was restricted to cytosolic endosome-like structures, 
failing 
to translocate to the mitochondria and induce apoptosis 24. Recently, four HER4 
isoforms has 
been identified with alternatively splicing within the intracellular cytoplasmic tail 
(isoform 
CYT1 and CYT2) and within the extracellular juxtamembrane region (isoforms JM-a 
and 
JM-b) 29. The two JM-a isoforms (JM-a, CYT1 and JM-a, CYT2) were overexpressed 
in a 
subset of primary breast cancers together with TACE 28 Over expression of JM-a, 
CYT2 
isoform promote HER4 phosphorylation and cancer cell proliferation even in the 
absence of 
ligand stimulation, whereas activation of the other 3 isoforms require ligand 
stimulation 28. 
The expression and function of TACE in cancer development and progression, 
including endocrine cancers, via its role in HER4-mediated cancer cell apoptosis, has, 
until 
now, been restricted to in vitro studies of breast cancer cell lines 23,24. In this study we 
initially identify TACE expression in breast, prostate and ovary carcinomas and 
further 
investigate if TACE expression is linked to apoptosis in ER-positive breast 
carcinomas. 
MATERIALS AND METHODS 
Patients 
Breast carcinomas were retrieved from 456 patients diagnosed 1980-1999 and treated 
with 
adjuvant tamoxifen. Estrogen receptor alpha (ER_) expression was confirmed using 
IHC 30 
in 422 cases (92.5%), of which 20 cases (4.4%) were ER_ negative. Data presented 
here 
relate only to the 402 ER positive breast carcinomas. Ovarian carcinomas were 
retrieved 
from 220 patients recruited in locally coordinated clinical trials 31-35. Prostate 
carcinoma 
specimens from 24 patients (24 hormone-sensitive/hormone-insensitive matched pairs; 
48 
carcinomas in total) were collected retrospectively. Ethical approval was obtained 
from the 
relevant ethics committees for all studies. 
Immunohistochemistry (IHC) 
IHC was performed on tissue microarrays (TMA; breast and ovary carcinomas) 
constructed 
as previously described 36 or on whole tissue sections (prostate carcinomas) using a 
standard 
immunoperoxidase procedure. The specificity of the TACE antibody was previously 
verified 
2,3. For detection of TACE expression, antigen retrieval was performed by heating 
sections 
overnight at 60ºC in 10 mM Tris, 0.25 mM EDTA, pH 9.0. Endogenous peroxidase 
activity 
was quenched with 1% hydrogen peroxide for 20 minutes, and non-specific binding 
blocked 
by casein (Vector Laboratories, CA, USA) for 20 minutes. Primary TACE antibody 
(C-15, 
Santa Cruz biotechnology Inc, CA, USA) was applied overnight at 4°C at a 
concentration of 
0.5 g/ml, and secondary rabbit anti-goat antibody (Vector Laboratories, CA USA; 
1:4000 
in casein) was applied for 1 hour at room temperature. EnVision (Dako, Glostrup, 
Denmark) 
was used for signal amplification, and positive staining visualized using 3.3- 
diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories, CA, USA). Nuclei 
were 
counterstained with haematoxylin before mounting. 
For detection of cleaved (active) caspase-3 expression, antigen retrieval was 
performed by microwaving the slides in 1 mM EDTA and 5 mM Trisma base, pH 8.0. 
Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 10 
minutes, 
and non-specific binding prevented by incubation in Serum-Free block (Dako, 
Glostrup, 
Denmark) for 1 hour. Primary antibody detecting cleaved caspase-3 (Abcam, 
Cambridge, 
UK) was applied overnight at 4°C at a concentration of 10 g/ml. EnVision (Dako, 
Glostrup, 
Denmark), was used for signal amplification and positive staining visualized using 
3.3- 
diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories, CA, USA). Nuclei 
were 
counterstained with haematoxylin before mounting. 
HER4 expression was evaluated on breast carcinomas using 2 antibodies, H4.77.16, 
raised against an extracellular epitope, and HFR1, raised against an intracellular 
epitope, 
both from Neomarkers. IHC was performed as previously described 30,36. The 
specificity of 
these two HER4 antibodies, their cellular localization and distribution in this patient 
cohort 
was previously published 36. 
TACE and HER4 expression was evaluated using a semi-quantitative weighted 
histoscore method as previously described 37 whereas the expression of cleaved 
caspase-3 
was measured by counting positive and negative tumor cells. Expression of TACE 
and 
cleaved caspase-3 is shown as percentage of positive tumor cells at any intensity. 
Positive 
TACE staining is defined as 10% or more TACE positive cells whereas a tumor is 
regarded 
as positive for cleaved caspase-3 if there are any positive cells. HER4 positivity was 
defined 
as previously described 30. 
TUNEL assay 
In situ TUNEL (terminal deoxynucleotidyl transferase-mediated in situ labeling) 
assay was 
performed on breast carcinomas using ApopTag Plus Peroxidase In Situ Apoptosis 
Detection 
Kit, Chemicon International) as previously described 23. In brief, devaxed and 
rehydrated 
tissues were proteinase K treated (20 µg/ml) for 15 minutes at room temperature and 
endogenous peroxidase activity quenched with 3% hydrogen peroxide for 5 minutes. 
Reaction buffer containing digoxigenin-labeled dNTPs and terminal deoxynucleotidyl 
transferase (TdT) enzyme was applied for 1 hour at 37ºC, and secondary anti-
digoxigenin 
conjugate was applied for 30 minutes at room temperature. Apoptosis positive cells 
were 
visualized using peroxidase substrate, and nuclei counterstained using 0.5% methyl 
green. 
The level of apoptosis was evaluated using a 0-400 scale. Intense apoptotic activity 
was 
defined as a score above 200. 
Statistical analysis 
All statistics were analyzed using SPSS statistical package (version 14.0 for 
Windows). 
Spearman rank tests were conducted to test the associations between expression of 
TACE, 
HER4, cleaved caspase-3 and TUNEL. Kaplan-Meier life tables with log-rank testing 
were 
conducted to assess overall and disease free survival of breast cancer patients. A value 
of p < 
0.05 was considered statistically significant. 
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RESULTS 
Clinical and pathological characteristics 
All breast cancer patients were treated with tamoxifen for a median of 5 years (range 
0.6 – 
18 years) and were followed-up for a median of 6.8 years (range 0.11-21.32 years). In 
addition to tamoxifen, 99/399 (24.8%) patients had chemotherapy (3 unknown) and 
110/399 
(27.57%) had radiotherapy (3 unknown). There were 74 breast cancer specific deaths 
and 
100 breast cancer relapses, 78 of which occurred during tamoxifen treatment 30. 
Median time 
to relapse for the ovarian cancer patients was 1.02 years (range 0.01- 11.2 years). 
Prostate 
carcinomas were collected from 24 patients that initially responded to androgen 
deprivation 
(defined by fall in PSA levels of at least 50%), but subsequently relapsed and had 
tissue preand 
post-therapy available for analysis (24 hormone-sensitive/hormone-insensitive 
matched 
pairs; 48 carcinomas in total). Median follow-up time was 4.44 years (range 0.50-7.92 
years) 
and the median time to biochemical relapse was 2.29 years (range 0.27-6.09 years). 
All 
patients were either medically (15 patients) or surgically (9 patients) castrated. 
TACE expression in endocrine cancers 
TACE expression was determined in breast, ovarian and prostate carcinomas (Figure 
1-3). In 
all three types of endocrine cancers, positive TACE staining was only observed in the 
cytoplasmic compartments of the invasive tumor, with no staining in normal tissue. 
The 
staining was often sporadic, reflecting the low percentage of positive cells, however, 
when 
TACE expression was seen it was often very intense. 
TACE expression was evaluated in 383/402 breast carcinomas (95%). The remaining 
19 cases were excluded from the study because of insufficient tumor material in the 
cores. 
TACE expression was observed in 183/383 carcinomas (47.8%) (Figure 1A and B). 
The 
median percentage of TACE positive tumor cells was 10 (interquartile range 3-20%; 
Figure 
1B). 
TACE expression was evaluated in 217/220 (98.6%) ovarian carcinomas. The 
remaining 3 cases were excluded from the study because of insufficient tumor 
material in the 
cores. Positive TACE expression was noted in 39/217 (18%) ovarian carcinomas with 
a 
median percentage of TACE positive tumor cells of 2 (interquartile range 0-7%) 
(Figure 2A 
and B). 
TACE expression was confirmed in 48 prostate carcinomas (24 matched tumors). 
Positive TACE expression was noted in 16/24 (66.7%) hormone-sensitive tumors and 
in 
17/24 (70.8%) hormone-insensitive tumors (Figure 3A). The median percentage of 
TACE 
positive cells was 30 (interquartile range 5-97.5%) in hormone-sensitive tumors 
compared to 
20 (interquartile range 2-90) in hormone-insensitive tumors, (p = 0.804; Figure 3B 
and 3C). 
Apoptosis in breast carcinomas 
Apoptotic activity was evaluated by both TUNEL assay and staining of cleaved 
caspase-3. 
TUNEL assay was evaluated in 363/402 (90%) breast carcinomas. The remaining 38 
cases 
were excluded from the study because of insufficient tumor material in the cores. 
Apoptotic 
activity was detected in 141/363 carcinomas (38.8%), including 21 carcinomas (5.8%) 
with 
intense apoptotic activity defined as a TUNEL score above 200. 
The expression of cleaved caspase-3 was evaluated in 359/402 (89%) breast 
carcinomas 
(Figure 4A and B). The remaining 43 cases were excluded from the study because of 
insufficient tumor material in the cores. Positive staining for cleaved caspase-3, 
defined as 
any staining of tumor cells, was detected in 316/359 carcinomas (88%) (Figure 4B). 
Only 
few cells in each tumor were stained positive for cleaved caspase-3. The median 
percentage 
of cleaved caspase-3 positive tumor cells (average between the 3 cores) was 1.4% 
(interquartile range 0.6-2.7%; Figure 4B). 
TACE and HER4 and apoptosis in breast carcinomas 
Data on HER4 expression in the same patient cohort has previously been reported 
including 
cellular distribution of the two antibodies 30,36. In the present study we correlated 
TACE 
expression and the level of apoptotic activity with the previously used HER4 
antibodies, 
raised against an extracellular (H4.77.16) or intracellular (HFR-1) epitope of HER4 36. 
A 
high level of cytoplasmic TACE was found mainly in tumors with high membrane 
HER4 
expression (p<0.001 for both HER4 antibodies, Spearman rank test, Figure 5), or in 
tumors 
with high levels of cleaved intracellular HER4 (4ICD) (p=0.016, HFR-1, Spearman 
rank 
test, Figure 5) or full length cytoplasmic HER4 (p=0.002, H4.77.16, Spearman rank 
test, 
Figure 5). No significant association between TACE expression and nuclear HER4 
expression was seen (p=0.050 and p=0.178 for HFR-1 and H4.77.16, respectively, 
Spearman 
rank test, data not shown). No significant association between cleaved caspase-3 and 
TACE 
expression or TUNEL and TACE (p=0.257 and p=0.824, respectively, Spearman rank 
test, 
data not shown) was seen. 
When measuring apoptotic activity by TUNEL assay, high levels of apoptotic 
activity was seen in tumors with high levels of full length cytoplasmic HER4 
(p=0.015, 
H4.77.16, Spearman rank test, Figure 5), but not in tumors with high levels of 4ICD 
(p=0.230, HFR-1, Spearman rank test, Figure 5). When using cleaved caspase-3 as a 
measurement for apoptotic activity, no significant association was seen between 
apoptotic 
activity and full length cytoplasmic HER4 (p=0.440, H4.77.16, Spearman rank test, 
Figure 
5) or 4ICD (p=0.884, HFR-1, Spearman rank test, Figure 5). No significant 
association 
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between apoptotic activity (TUNEL and cleaved caspase-3) and membrane or nuclear 
HER4 
expression was seen (data not shown). 
TACE expression and patient outcome in breast cancer 
To analyze the association between TACE expression and patient outcome, patients 
were 
divided into those with positive or negative TACE expression, defined as above and 
below 
10% stained cells at any intensity. Using this definition, no correlation between TACE 
expression and disease-free (p=0.877, log-rank test, data not shown) or overall 
(p=0.123, 
log-rank test, data not shown) patient survival were noted. 
Apoptosis and patient outcome in breast cancers 
To analyze the association between apoptotic activity and patient outcome, patients 
were 
divided into those with or without apoptosis, defined as patients with or without any 
cleaved 
caspase-3 tumor expression or patients with a TUNEL score above or below 200. 
Using this 
definition, no correlation between apoptotic activity and disease-free or overall 
survival was 
observed (data not shown). 
DISCUSSION 
TACE was originally identified as the proteinase responsible for ectodomain shedding 
of 
pro-TNF_ in inflammatory diseases (reviewed in 1). Recent data has, however, 
revealed that 
upon sequential cleavage by TACE and presenilin-dependent _-secretase complex, 
the 
intracellular domain of HER4 is released 8,25-27. The association of HER4 expression 
with 
clinical outcome has been suggested to depend on whether HER4 is cleaved (4ICD) 
or 
remains intact on the cell surface. 4ICD, translocated to the nucleus, has been 
associated 
with a worse clinical outcome 38. 
We have previously demonstrated in vitro, that 4ICD in normal breast development 
activates and complexes with STAT5A in the cytoplasm to function as a nuclear 
chaperone 
for STAT5A, thus regulating STAT5A-dependent transcriptional activation of the _-
casein 
promoter 14,24. We also identified 4ICD in the cytoplasmic compartment as a pro-
apoptotic 
BH3-only protein in breast cancer cell lines that converts apoptotic signals at the 
mitochondria, initiating mitochondrial dysfunction and cell death 23. In the current 
study we 
demonstrate TACE expression in tumor cells of breast, ovary and prostate carcinomas. 
To 
further evaluate the in vivo role of TACE and HER4 in mediating breast cancer 
apoptosis, 
we have used two HER4 antibodies. The H4.77.16 antibody, raised against an 
extracellular 
fragment, detects predominantly the intact (non-cleaved) membranous HER4 and the 
HFR-1 
antibody, raised against an intracellular epitope, detects intact membranous and the 
cleaved 
cytoplasmic (4ICD) form of HER4. Using this in vivo approach we identified a link 
between 
TACE and membrane or cytoplasmic intact HER4 expression as well as between 
TACE and 
cleaved (4ICD) HER4 in breast carcinomas. The association between 4ICD and 
TACE 
expression supports a role for TACE in mediating cleavage of membrane-bound 
HER4 in 
breast cancers and thereby links TACE to the in vivo function of 4ICD e.g. apoptosis 
(Figure 
5). This is a support of our previous study showing that proteolytic processing of  
the cell surface by TACE and presenilin-dependent _-secretase complex, generating 
cytosolic 4ICD, is necessary for HER4-mediated apoptosis 24. We have also 
previously 
demonstrated that unprocessed HER4 accumulates in cytosolic endosome-like 
structures 24. 
As TACE has been localized within endosomes 39, the observed correlation between 
TACE 
and cytoplasmic intact HER4 detected by the H4.77.16 antibody could indicate 
colocalization 
of TACE and HER4 in endosomes. 
In the present study we measured apoptosis in breast carcinomas using both TUNEL 
and staining of active (cleaved) caspase-3. Previous studies have shown that TUNEL 
detects 
a markedly higher level of apoptosis than cleaved caspase-3 40,41, which may be 
related to 
detection of other forms of cell death i.e. necrosis or detection of DNA breaks that 
occur 
during mitosis or DNA repair. Conversely, non-caspase-3 mediated apoptotic 
pathways have 
also been identified which may suggest that caspase-3 does not detect all apoptotic 
cells 42. 
Taken together, these data challenge assumptions regarding optimal methodologies 
for 
detection of apoptosis. At present, however, detection of cleaved caspase-3 is 
regarded as a 
more reliable method than the TUNEL assay, despite the fact that caspase-3 may 
underestimate the level of apoptosis 40,41. Using TUNEL assay and detection of 
cleaved 
caspase-3 as two different measurements of apoptosis we were, in the present study, 
unable 
to detect any significant correlation between cleaved HER4 (4ICD) and apoptosis. 
Previously, we have, however, shown a link between 4ICD and apoptosis in vitro by 
measuring chromatin condensation (visual detection of morphological signs of 
apoptosis 
following DAPI staining) in human breast cancer cells transfected with HER4 23. 
Further 
evaluation of the mechanism for HER4 cleavage and the role of cleaved HER4 in 
mediating 
breast tumor cell apoptosis in vivo, is clearly required 
Activated HER4 has previously been linked to antiproliferative responses 20 and the 
induction of apoptosis, via TACE/HER4, might therefore be restricted to highly 
proliferating 
tumors. TACE can also activate HER receptor ligands, such as pro-TGF-_, which 
makes 
TACE able to mediate both cancer cell apoptosis and proliferation via EGFR 
activation. This 
could explain the lack of association between TACE and apoptotic activity in this 
cohort of 
ER positive, low risk and poorly proliferating tumors. Instead TACE may mediate 
tumor cell 
progression via activating signal transduction pathways. The lack of association 
between 
TACE expression and apoptotic activity might also be explained by the presence of 
different 
HER4 spliced isoforms which are resistant to TACE cleavage 28. 
In addition to breast cancers, we also determined TACE expression in other 
endocrine cancers. Positive TACE expression was observed in 39/217 (18%) of 
ovarian 
carcinomas, whilst 16/24 (66.7%) and 17/24 (70.8%) hormone-sensitive and 
hormoneinsensitive 
prostate carcinomas, respectively, showed positive TACE expression. Prostate 
cancers appear, therefore, to be associated with increased levels of TACE expression, 
relative to breast and ovarian cancers, but there is no obvious association with 
hormone 
resistance. Presumably, TACE could have a role in tumor progression by activating 
HER 
ligands in these endocrine cancers, as shown previously in breast cancer 9, however, 
to 
further investigate if TACE plays a similar role in mediating HER4 ectodomain 
shedding 
and apoptosis in endocrine cancers, larger and well-characterized cohorts of prostate 
and 
ovarian carcinomas need to be analyzed. 
In this study we have demonstrated TACE expression in three different endocrine 
cancers, breast, ovary and prostate. We have also shown that TACE expression in 
breast 
carcinomas correlates with membrane HER4 expression and internalized and cleaved 
HER4. 
HER4 is a pluripotent protein in normal physiology including breast development and 
lactation as well as in cancers where it is able to modulate both cancer cell apoptosis 
and cell 
proliferation. TACE can activate HER ligands by proteolytic processing and thereby 
also 
plays a role in tumor progression. To further elucidate the role of TACE in endocrine 
cancers, more information is required. Based on our observations and the current 
literature 
we hypothesize a complex interaction between TACE and HER signaling mediated 
via the 
ability of TACE to cleave HER ligands, promoting cancer progression in some tumors, 
and 
cleavage of HER4, again involving TACE but in this context promoting apoptosis and 
reducing the aggressive potential of tumors. 
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Figure legends 
Figure 1 
(A) Photomicrographs of IHC staining in breast carcinoma showing only cytoplasmic 
TACE 
protein expression. Original magnification: x 400. (B) Histogram showing the number 
of 
breast cancer patients and the percentage of TACE positive cancer cells. 
Figure 2 
(A) Photomicrographs of IHC staining in ovary carcinoma showing only cytoplasmic 
TACE 
protein expression. Original magnification: x 400. (B) Histogram showing the number 
of 
ovary cancer patients and the percentage of TACE positive cancer cells. 
Figure 3 
(A) Photomicrographs of IHC staining in prostate carcinoma showing only 
cytoplasmic 
TACE protein expression. Original magnification: x 400. (B) Histogram showing the 
number of hormone sensitive patients and the percentage of TACE positive cancer 
cells. (C) 
Histogram showing the number of hormone insensitive patients and the percentage of 
TACE 
positive cancer cells. 
Figure 4 
(A) Photomicrographs of cleaved caspase-3 (apoptotic activity) in breast carcinoma. 
Original 
magnification: x 400. (B) Histogram showing the number of breast cancer patients 
and the 
percentage of cells stained positive for cleaved caspase-3. 
Figure 5 
